Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
11000 participants
OBSERVATIONAL
2024-03-01
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma
NCT02851784
Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma
NCT04152356
The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study
NCT07078292
Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
NCT06542796
Therapeutic Effects of Immuno-targeted Therapy Combined With or Without RT for HCC
NCT06639971
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
retrospective cohort
The patients in the retrospective cohort are hepatocellular carcinoma patients who have been previously treated with immunotherapy-based combination regimens. It is anticipated that approximately 10,000 cases will be included.
Immunotherapy-based Combination Therapies
immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions
prospective cohort
The patients included in the prospective cohort are hepatocellular carcinoma patients who are being evaluated by researchers to determine the potential benefits of undergoing immunotherapy-based combination treatment regimens. It is anticipated that approximately 1,000 cases will be enrolled.
Immunotherapy-based Combination Therapies
immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Immunotherapy-based Combination Therapies
immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Hepatocellular carcinoma diagnosed by pathology or imaging.
3. Patients assessed by researchers as potentially benefiting from receiving immunotherapy-based combination regimens.
4. For participants who have previously received treatment according to this protocol, a comprehensive pre-treatment assessment is required, including demographic information, tumor history, medical history, and baseline imaging examinations.
5. Patients voluntarily enroll in this study.
Exclusion Criteria
2. Other conditions regimented at investigators' discretion.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital with Nanjing Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-SR-876
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.